



UNITED STATES PATENT AND TRADEMARK OFFICE

2/1
UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/049,227	09/23/2002	Allan J Clarke	P32374	9571
20462	7590	03/29/2005	EXAMINER	
SMITHKLINE BEECHAM CORPORATION CORPORATE INTELLECTUAL PROPERTY-US, UW2220 P. O. BOX 1539 KING OF PRUSSIA, PA 19406-0939				TRAN, SUSAN T
ART UNIT		PAPER NUMBER		
		1615		
DATE MAILED: 03/29/2005				

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary	Application No.	Applicant(s)
	10/049,227	CLARKE ET AL.
	Examiner	Art Unit
	Susan T. Tran	1615

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --
Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) Responsive to communication(s) filed on 22 November 2004.
 2a) This action is FINAL. 2b) This action is non-final.
 3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) Claim(s) 38-52,54-58 and 60-72 is/are pending in the application.
 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
 5) Claim(s) _____ is/are allowed.
 6) Claim(s) 38-52,54-58,60-69,71 and 72 is/are rejected.
 7) Claim(s) 70 is/are objected to.
 8) Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) The specification is objected to by the Examiner.
 10) The drawing(s) filed on _____ is/are: a) accepted or b) objected to by the Examiner.
 Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
 Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
 a) All b) Some * c) None of:
 1. Certified copies of the priority documents have been received.
 2. Certified copies of the priority documents have been received in Application No. _____.
 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- | | |
|-----------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------|
| 1) <input type="checkbox"/> Notice of References Cited (PTO-892) | 4) <input checked="" type="checkbox"/> Interview Summary (PTO-413) |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | Paper No(s)/Mail Date. <u>03/22/05</u> . |
| 3) <input checked="" type="checkbox"/> Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)
Paper No(s)/Mail Date <u>11/22/04</u> . | 5) <input type="checkbox"/> Notice of Informal Patent Application (PTO-152) |
| | 6) <input type="checkbox"/> Other: _____ |

DETAILED ACTION

Receipt is acknowledged of Information Disclosure Statement, Amendment, and Request for Extension of Time filed 11/22/04.

Information Disclosure Statement

The information disclosure statement (IDS) submitted on 11/22/04 was filed after the mailing date of the Non-Final Office Action on 05/17/04. The submission is in compliance with the provisions of 37 CFR 1.97. Accordingly, the information disclosure statement is being considered by the examiner.

Claim Rejections - 35 USC § 112

The 112, first paragraph rejection of claim 68 has been withdrawn in view of applicant's remark dated 11/22/04 at page 12. According to the remark, both plug portions are plug portions of the same linker, and therefore, the finished product is necessarily an integrated dosage form having two capsule compartments that are separate in the sense that they are spaced from each other, but not separate in the sense that they are relatively movable.

Claim Rejections - 35 USC § 102

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless –

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

Claims 38, 43, 44, 58 and 61-68 are rejected under 35 U.S.C. 102(b) as being anticipated by Graham US 5,085,033.

Graham discloses a capsule formulation comprising active agent in matrix material (see abstract, column 3, lines 9-25). The active agent and matrix materials are filled in capsule halves, the capsule halves are sealed by the application of electromagnetic radiation whereupon the capsule halves are welded to each other (column 4, lines 19-29). Column 8 and examples 1-14 disclose the process for filling the capsule.

Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

Claims 38-41, 51, 52, 54-58, 61-69, 71 and 72 are rejected under 35 U.S.C. 103(a) as being unpatentable over Goodhart et al. US 5,074,426, in view of Sivaramakrishnan et al. WO 90/11070 (Sivara).

Goodhart discloses a multi-units capsule dosage comprising first and second capsule units (column 3, lines 17-19). Column 4, lines 1-31 disclose the process of preparing the capsule units comprising filling the two capsule units with medicinal

preparation, applying adhesive paste on top of the medicinal preparation, turning the capsule units inwardly towards each other with the adhesive paste abutting each other, and adhesive paste would be applied to secure the capsule units together (Fig. 7). The multi-capsule units can be connected by separately molded section which is sealed to the capsule units by solvent welding (column 4, lines 28-31, Fig 3). Goodhart also teach there is an intermediated molded locking part used to secure the two capsule units together (column 4, lines 44-66). Furthermore, the capsule units are made with a female member (68) and male member (70) to provide a tight friction fit (Figs. 13&14, column 5, lines 5-16). Goodhart also teach the capsule units are detachable joined by adhesive, banding, or locking mechanical means (see abstract).

Goodhart is relied upon for the reason stated above. Goodhart teaches the capsule can be filled with pellets, granules or viscous or liquid substance (column 3, lines 63-65), however, the reference is silent as to the teaching of capsule containing solid matrix as claimed in claims 40 and 41.

Sivara teaches a controlled release delivery device comprising a water-soluble capsule surrounding an inner capsule containing solid matrix core (see abstract, page 5, lines 8-19, and page 10, lines 13-34). The solid matrix core can be in the form of microcapsule (page 7, lines 1-17 and page 9, lines 14-34). Sivara also teach different wall thickness of the matrix shell that would promote different rates of release of active agent (page 11, lines 25-34). Thus, it would have been obvious for one of ordinary skill in the art to modify the capsule composition of Goodhart to encapsulate the solid matrix

in view of the teachings of Sivara with the expectation of providing a capsule formulation containing multi-unit capsule compartments suitable for multi-release rates of active agents.

Claims 38-52, 54-58, 60-69, 71 and 72 are rejected under 35 U.S.C. 103(a) as being unpatentable over Goodhart et al., in view of Amidon et al. US 5,674,530.

Goodhart is relied upon for the reasons stated above. The reference is silent as to the teaching of the linker as claimed in claims 44-50.

Amidon discloses a delivery system comprising multiple chambers and multiple plugs (linker) (column 3, lines 59 through column 4, lines 1-36). Thus, it would have been obvious for one of ordinary skill in the art to modify the capsule formulation of Goodhart using the plug in place of the adhesive paste in view of the teaching of Amidon with the expectation of providing a true pulsatile delivery system that increases in bioavailability and provides optimal dosing schedule for two or more drugs.

It is noted that the cited references do not teach the wall thickness of sub-unit (multi-compartment). However, changes in size or shape is not patentably distinct the claimed invention because it would have been obvious for one of ordinary skill in the art to, by routine experimentation determine a suitable wall thickness depending upon the desirability of the permeability rate of the drug.

Response to Arguments

Applicant's arguments filed 11/22/04 have been fully considered but they are not persuasive.

Applicant argues that in Graham, there is no disclosure of the specific joint structure, as well as the drug substances in at least two of the sub-units are different. In contrast, in Graham, the capsule ingredients are apparently the same in both halves of the capsule. According to applicant's argument, it was suggested to incorporate claims 42 and 70 into all independent claims to place the application in condition for allowance. However, applicant disagreed to the incorporation of claim 70 for the reason that the drug substances in at least two of the sub-units of the claimed invention are *the same*.

Applicant argues that the Goodhart capsule can be taken apart, as intended, whereas the claimed capsule cannot be taken apart without spilling the capsule contents. In response to applicant's argument that the reference does not show certain feature of applicant's invention, it is noted that the feature upon which applicant relies (i.e., capsule cannot be taken apart) is not recited in the rejected claims. Although the claims are interpreted in light of the specification, limitations from the specification are not read into the claims. See *In re Van Geuns*, 988 F.2d 1181, 26 USPQ2d 1057 (Fed. Cir. 1993).

Claims Allowable

Claim 70 is objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims.

Conclusion

Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, **THIS ACTION IS MADE FINAL**. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the date of this final action.

Correspondence

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Susan T. Tran whose telephone number is (571) 272-0606. The examiner can normally be reached on M-R from 6:00 am to 4:30 pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Thurman K. Page, can be reached at (571) 272-0602. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

THURMAN K. PAGE
SUPERVISORY PATENT EXAMINER
TECHNOLOGY CENTER 1600